Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL/VLDL catabolism in individuals with type 2 diabetes: a randomised in vivo kinetic study.

Fiche publication

Date publication

juillet 2026

Journal

Diabetologia

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DUVILLARD Laurence , Dr PAIS DE BARROS Jean-Paul

Tous les auteurs :
Vergès B, Rouland A, Bouillet B, Pais de Barros JP, Fourmont C, Buffier P, Jourdan T, Vergas V, Duvillard L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42467086

Résumé

SGLT2 inhibitors reduce atherosclerosis, but their effect on lipid metabolism remains unclear. Animal studies have suggested that SGLT2 inhibitors may decrease LDL catabolism by reducing the hepatic expression of LDL receptors. However, the effect of SGLT2 inhibitors on LDL metabolism, and more widely on all ApoB-containing lipoproteins, remain unknown in humans. This prompted us to study the effect of the SGLT2 inhibitor dapagliflozin on the metabolism of ApoB100-containing lipoproteins in individuals with type 2 diabetes.